Concord Biotech (Mid Cap) Share Target 2025, 2026 To 2035
|
Concord Biotech Limited |
|||
|
Price: ₹2,160.45 (-0.38%) | ||
| 52 Week Low: ₹1,327.05 52 Week High: ₹2,664.00 |
|||
| Market Capital: 19,853.5 Crore (Midcap) | |||
| Healthcare -> Biotechnology | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Concord Biotech Share Price Target For 2025
- 1.1.1: Concord Biotech Share Price Target Table For 2025
- 1.1.2: Short-Term Technical Outlook
- 1.2: Concord Biotech Share Price Target For 2026
- 1.2.1: Concord Biotech Share Price Target Table For 2026
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Concord Biotech Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
- 3: Concord Biotech Brief Company Overview
- 4: Concord Biotech Financial Performance
- 4.0.1: Is Concord Biotech A Good Buy For Long Term?
Concord Biotech, a Mid Cap company in the Biotechnology Industry has delivered 48.4% returns in 1-year showing 18.2% quarterly revenue growth with 30.2% profit margin.
To predict the Concord Biotech's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Concord Biotech Share Price Target For 2025
The line chart displays the monthly closing prices of Concord Biotech with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Concord Biotech shares in 2025, see the table below.
Concord Biotech Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 2446.62 (+13.24%) | Price Action: Chart |
| 2025 Target 2 | 2401.0 (+11.13%) | Price Action: Dec 2024 High |
| 2025 Target 1 | 2361.1 (+9.27%) | Price Action: 23 Sep 2024 Low |
| Current Price | 2160.45 | Concord Biotech's share price as of 21 Jan 2025 |
| Stop Loss 1 | 2066.45 (-4.36%) | Price Action: 30 Sep 2024 High |
| Stop Loss 2 | 2045.0 (-5.35%) | Price Action: 22 Nov 2024 High |
| Stop Loss 3 | 2023.8 (-6.33%) | Price Action: 28 Nov 2024 Low |
Short-Term Technical Outlook
Current Technical Position: Concord Biotech is showing mixed momentum signals near key moving averages.
Key Technical Level: The 25-day moving average at ₹2185.96 serves as the nearest technical reference point.
Historical Returns: 3-month: +18.04% | 6-month: +31.7% | 1-year: +48.39%
Concord Biotech Share Price Target For 2026
The line chart displays the monthly closing prices of Concord Biotech with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Concord Biotech shares in 2026, see the table below.
Concord Biotech Share Price Target Table For 2026
| Level | Value | Analysis |
|---|---|---|
| 2026 Target 3 | 3401.73 (+57.45%) | Price Action: Chart |
| 2026 Target 2 | 3338.3 (+54.51%) | Price Action: Chart |
| 2026 Target 1 | 3305.25 (+52.98%) | Fibonacci Extension Level 64.90% |
| Current Price | 2160.45 | Concord Biotech's share price as of 21 Jan 2025 |
| Stop Loss 1 | 1884.89 (-12.76%) | Technical Indicator: MA150 |
| Stop Loss 2 | 1862.95 (-13.78%) | Price Action: 09 Sep 2024 High |
| Stop Loss 3 | 1843.35 (-14.68%) | Price Action: 10 Sep 2024 Low |
Long-Term Technical Outlook
52-Week Range Analysis: Concord Biotech is currently trading at 62.3% of its 52-week range (₹1327.05 - ₹2664).
Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.
Long-Term Performance: 1-year: +48.39% | 3-year: NA | 5-year: NA
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Concord Biotech Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹2,160.45 | ||
| 2025 | ₹3,039.53 | +40.68% | ₹3,085.12 |
| 2026 | ₹5,138.71 | +69.06% | ₹5,215.79 |
| 2027 | ₹7,216.91 | +40.44% | ₹7,325.16 |
| 2028 | ₹10,587.53 | +46.7% | ₹10,746.34 |
| 2029 | ₹14,626.95 | +38.15% | ₹14,846.35 |
| 2030 | ₹19,530.36 | +33.52% | ₹19,823.32 |
| 2031 | ₹25,368.50 | +29.89% | ₹25,749.03 |
| 2032 | ₹34,739.08 | +36.93% | ₹35,260.17 |
| 2033 | ₹46,179.79 | +32.93% | ₹46,872.49 |
| 2034 | ₹62,573.49 | +35.49% | ₹63,512.09 |
| 2035 | ₹74,600.74 | +19.22% | ₹75,719.75 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Concord Biotech Brief Company Overview
Concord Biotech Limited: A Pioneer in Biopharmaceuticals Established in 1984, Concord Biotech Limited is a reputable biopharma company based in India. With a global market presence, they specialize in research and development, manufacturing, marketing, and sale of...
pharmaceuticals. Diverse Product Range Fermentation-based active pharmaceutical ingredients Immunosuppressants (tacrolimus, mycophenolate mofetil, etc.) Oncology (temsirolimus, everolimus, etc.) Anti-bacterial (mupirocin, vancomycin hydrochloride, etc.) Anti-fungal (anidulafungin, caspofungi, etc.) Commitment to Innovation Concord Biotech is dedicated to providing cutting-edge pharmaceutical solutions. Their contract research and manufacturing services leverage advanced fermentation and semi-synthesis technologies. Strong Industry Reputation The company has established a strong reputation in the industry for its quality products and reliable services. Their commitment to innovation and customer satisfaction has earned them recognition as a leading player in the biopharma sector.Concord Biotech Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 19,853.5 Crore | Market valuation of Concord Biotech's shares. |
| Revenue (TTM) | 1,085.74 Crore | Total revenue generated by Concord Biotech over the past twelve months. |
| Net Income (TTM) | +327.92 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +39.77% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +30.2% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+18.2% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
+18.2% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
0.21 | Company's total debt divided by total shareholder equity. |
| Total Debt | 3.42 Crore | Sum of Concord Biotech's current & long-term financial obligations. |
| Total Cash | 283.74 Crore | Total amount of liquid funds available to Concord Biotech. |
Is Concord Biotech A Good Buy For Long Term?
Concord Biotech, a mid-cap stock with a market capitalization of ₹19,853.5 crore, shows strong financial health. Its ₹327.92 crore net profit in the last twelve months (TTM), coupled with a healthy 30.2% profit margin and robust cash balance of ₹283.74 crore (Q2 2024-25), indicates positive performance. Impressive 12-month returns (75.79%) are noteworthy, though longer-term data is missing. While the low debt of ₹3.42 crore is favorable, a comprehensive risk assessment is needed before recommending a long-term buy. Based on current data, Concord Biotech presents itself as a potentially good buy for long-term investors with moderate risk tolerance.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
